Endo International plc – (NASDAQ:ENDP) (TSE:ENL) shares gapped down prior to trading on Friday . The stock had previously closed at $8.29, but opened at $8.07. Endo International shares last traded at $7.92, with a volume of 7473100 shares trading hands.

A number of research firms have recently weighed in on ENDP. ValuEngine raised Endo International from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. Goldman Sachs Group began coverage on Endo International in a research note on Thursday, September 28th. They issued a “sell” rating and a $7.00 price target on the stock. Zacks Investment Research downgraded Endo International from a “buy” rating to a “hold” rating in a research note on Thursday, October 12th. Piper Jaffray Companies reissued a “hold” rating and issued a $9.00 price target on shares of Endo International in a research note on Sunday, September 17th. Finally, Leerink Swann started coverage on Endo International in a research note on Tuesday, January 2nd. They set an “outperform” rating and a $12.00 price objective on the stock. Three investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Endo International presently has an average rating of “Hold” and a consensus target price of $11.27.

The firm has a market cap of $1,768.64, a P/E ratio of -0.35, a P/E/G ratio of 2.72 and a beta of 0.59. The company has a debt-to-equity ratio of 10.78, a current ratio of 1.08 and a quick ratio of 0.86.

Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its quarterly earnings data on Thursday, November 9th. The company reported $0.91 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $0.06. The business had revenue of $786.90 million for the quarter, compared to the consensus estimate of $794.93 million. Endo International had a positive return on equity of 66.98% and a negative net margin of 126.97%. The firm’s revenue was down 11.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.01 EPS. research analysts forecast that Endo International plc – will post 3.67 EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in ENDP. Sivik Global Healthcare LLC bought a new position in Endo International during the 2nd quarter worth about $2,793,000. Diamond Hill Capital Management Inc. increased its holdings in Endo International by 46.8% during the 3rd quarter. Diamond Hill Capital Management Inc. now owns 716,670 shares of the company’s stock worth $6,138,000 after purchasing an additional 228,426 shares in the last quarter. River & Mercantile Asset Management LLP increased its holdings in Endo International by 116.3% during the 3rd quarter. River & Mercantile Asset Management LLP now owns 358,540 shares of the company’s stock worth $3,071,000 after purchasing an additional 192,790 shares in the last quarter. Van ECK Associates Corp increased its holdings in Endo International by 67.1% during the 3rd quarter. Van ECK Associates Corp now owns 340,991 shares of the company’s stock worth $2,921,000 after purchasing an additional 136,873 shares in the last quarter. Finally, Quantitative Investment Management LLC bought a new position in Endo International during the 2nd quarter worth about $1,344,000. Hedge funds and other institutional investors own 93.06% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Endo International (ENDP) Shares Gap Down to $8.07” was posted by Watch List News and is the property of of Watch List News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.watchlistnews.com/endo-international-endp-shares-gap-down-to-8-07/1806596.html.

Endo International Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with Analyst Ratings Network's FREE daily email newsletter.